TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02436811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written form instruction
Description: 60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written form instruction
Description: 60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized oral instruction
Description: 60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized oral instruction
Description: 60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: 60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: 60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
Study: NCT01258192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel plus cisplatin
Description: neo-chemotherapy program:Albumin-bound paclitaxel:100 mg/m2, IV (in the vein) on days 1,8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle.Number of Cycles: 2 cycles before operation.If it is effective ,2 cycles will be given in 6 weeks after radical resection.
Study: NCT03430193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIRM
Description: FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward.~PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
Study: NCT05182645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle-modification
Description: The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of crohn's disease patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: waiting control group
Description: Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
Study: NCT02227875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan's insulin glargine
Description: Patients who are randomized to receive Mylan's insulin glargine during the comparative phase will receive the same dose as the dose of Lantus® received during the screening period. The recommended starting dose of Mylan's insulin glargine or Lantus®, in patients with T2DM who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted every week if essential.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
Study: NCT04023331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SARTATE
Description: 64Cu-labelled MeCOSar-Tyr3-octreotate
Study: NCT03658135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: BIIB092 is an investigational monoclonal antibody directed at tau protein

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient
Study: NCT00604409

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIRT
Description: Undergo SIRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study: NCT02208362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm 1: IL13Ra2-specific CAR Tcm cells
Description: Given via intratumoral catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm 2: IL13Ra2-specific CAR Tcm cells
Description: Given via intratumoral/intracavitary catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm 3: IL13Ra2-specific CAR Tcm cells
Description: Given via intraventricular catheter
Study: NCT01804101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03107013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BTD-001
Description: Carbon-14 labeled BTD-001
Study: NCT02462421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.
Study: NCT02208362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm 4: IL13Ra2-specific CAR Tcm cells
Description: Given via intratumoral or intracavitary, and via intraventricular catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm 5: IL13Ra2-specific CAR Tn/mem cells
Description: Given via intratumoral or intracavitary, and via intraventricular catheter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Correlative studies
Study: NCT01624012

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV NAVA
Description: Non invasive ventilation with neurally adjusted ventilatory assist

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal continuous positive airway pressure
Description: Noninvasive respiratory support with continuous positive airway pressure
Study: NCT02462421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin
Description: A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.
Study: NCT01966042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local sedation
Description: All subjects enrolled in the study underwent local sedation for bone marrow aspiration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: All subjects enrolled in the study underwent bone marrow aspiration after they had been anesthetized from the posterior iliac crest. The sample was aspirated into a series of sterile syringes and brought to the cell processing room/laboratory. The processing was in accordance to the Standard Operating Procedure developed observing Good Practice Guidelines.
Study: NCT02208362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Correlative studies
Study: NCT01966042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minithoracotomy
Description: The surgical procedure used as cardiac access route was the left anterolateral thoracotomy or left anterior minithoracotomy, depending on the segment of the left ventricle to be treated, allowing the good access to the viable myocardial areas.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells infusion
Description: Once the subject had his or her chest opened and the coronary anatomy reviewed by examination of the pre-operatory nuclear scan to define the area of ischemia, the surgeon drew up the cells into a series of syringes and injected the entire contents of the cell preparation in a series of injections directly into the myocardium.
Study: NCT00004143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath, Chemo and/or TBI Allo SCT
Description: Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath, Chemo and/or TBI Allo SCT
Description: Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
Study: NCT00232115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 %

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle cream (placebo)
Study: NCT00567281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Rapid 2 system triggering Magstim Super Rapid system
Description: Week 1 treatment includes rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim Rapid-2 system triggering Magstim Super Rapid system
Description: Week 1 includes repetitive rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with sham rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, sham rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
Study: NCT02453425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP 60 mmHg
Description: Norepinephrine adjusted to reach MAP 60 mmHg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP 75 mmHg
Description: Norepinephrine adjusted to reach MAP 75 mmHg
Study: NCT02208362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Correlative studies
Study: NCT02453425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP 90 mmHg
Description: Norepinephrine adjusted to reach MAP 90 mmHg
Study: NCT03385746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polyamide
Description: metal reinforced polyamide denture base material
Study: NCT01804101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cytarabine-Daunorubicin CPX-351
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cytarabine-Daunorubicin CPX-351
Description: Given IV
Study: NCT03385746

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heat cured acrylic resin
Description: conventional heat cured acrylic resin denture base material
Study: NCT03850509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPS-2071
Description: OPS-2071 300 mg, tablets, orally, BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPS-2071
Description: OPS-2071 300 mg, tablets, orally, BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPS-2071
Description: OPS-2071 300 mg, tablets, orally, BID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: OPS-2071-matched placebo, tablets, orally, BID.
Study: NCT01329419

Intervention type: DRUG
Intervention: adefovir dipivoxil
Description: Basically there is no treatment allocation. Subjects who would be administered of adefovir at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT02208362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04594369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib 10 mg
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib 25 mg
Description: Oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Brensocatib-matching oral tablet.
Study: NCT03892174

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment protocol with adsorption
Description: Adsorption while patients are in the OR on the extracorporeal circuit
Study: NCT00656604

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Description: at the time of each procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumpectomy or mastectomy
Description: removal of breast tumor or removal of the entire breast in which the tumor is located

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Prior to initiation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: histopathologic examination
Description: After the breast tumor has been removed, examination of the tumor under a microscope to determine the type and grade of breast cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance spectroscopy
Description: Prior to initiation of treatment
Study: NCT04209725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Given during the induction and consildation phase and will consist of 44 mg/m\^2 daunorubicin with 100 mg/m\^2 cytarabine administered intravenously on Days 1, 3, and 5 during induction phase and Days 1 and 3 of consolidation phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given during induction, consolidation, and maintenance phases and will be taken orally at a dose of 30mg on Days 8-21 of induction phase, Days 6-21 of consolidation phase, and daily in maintenance phase.
Study: NCT01232010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil
Description: 50mg Single Oral Dose of

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil
Description: 50mg Single Oral Dose of
Study: NCT03257332

Intervention type: PROCEDURE
Intervention: Low Anterior Resection for Rectum Cancer
Description: Subjects should have received curative surgery for rectal cancer (low anterior resection) with/with-out adjuvant (radiation/chemo) therapy.
Study: NCT00114179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT03233802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Assess & Treatment (IATP)
Description: See previous description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Packaged Cognitive-Behavioral (PCBT)
Description: See previous description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management (CaseM)
Description: See previous description
Study: NCT02605564

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten Free Diet
Description: Gluten Free Diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo No intervention, standard T1DM diet
Study: NCT03535064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Hygiene Workshop
Description: Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
Study: NCT04265742

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: bone densitometry
Description: Bone Mineral Density (BMD), body composition, vertebral fractures

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: bone densitometry
Description: Bone Mineral Density (BMD), body composition, vertebral fractures

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: bone densitometry
Description: Bone Mineral Density (BMD), body composition, vertebral fractures
Study: NCT02278939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Filipinos Fit and Trim Weight Loss Program
Description: This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Filipinos Fit and Trim Weight Loss Program
Description: This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.